Semaglutide (Ozempic/Wegovy) Cuts Major Heart Risks Independent of Weight Loss, SELECT Trial Analysis Confirms

A recent research study conducted by University College London (UCL) has unveiled a groundbreaking finding from the SELECT trial: the cardiovascular benefits of semaglutide in patients with overweight or obesity and pre-existing cardiovascular disease (but without diabetes) are not primarily dependent on the magnitude of weight loss achieved.

Key Findings of the SELECT Trial Analysis

The analysis focused on the efficacy of once-weekly semaglutide 2.4 mg (marketed as Wegovy for weight management) compared to a placebo in patients aged 45 or older with a BMI of at least $27 \text{ kg/m}^2$.

Primary Outcome: Semaglutide significantly reduced Major Adverse Cardiovascular Events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke.
Decoupling the Benefit: The analysis showed that the reduction in MACE risk was apparent early in the study and occurred at all levels of baseline weight or waist circumference.
No Link to Early Weight Loss: Crucially, the researchers demonstrated that early weight loss (changes in adiposity during the first 20 weeks) was not related to the cardiovascular benefit observed after 20 weeks.
Modest Link to Central Adiposity: While a linear relationship was found between the treatment effect and a decrease in waist circumference (a measure of central adiposity), this decrease only accounted for or mediated about 33% of the total semaglutide treatment effect.

Implications for Mechanism of Action

The finding suggests that semaglutide’s cardiovascular protection is largely due to mechanisms beyond simple reduction in body fat. Researchers propose several potential non-adiposity mechanisms:

Direct Effects: Semaglutide likely exerts direct effects on the cardiovascular system, including improved endothelial function and interference with other atherosclerotic pathways (plaque buildup in arteries).
Confirmation with Other Drugs: The results are consistent with studies of other GLP-1 Receptor Agonists (GLP-1 RAs) and different drug classes, which have also demonstrated cardiovascular benefits with little to no associated weight loss.

Impact on Clinical Practice and Policy

The researchers noted that these findings have substantial implications for clinical practice and health-care policy:

Expanded Patient Eligibility: Since most patients treated for cardiovascular disease have a BMI of at least $27 \text{ kg/m}^2$, the findings suggest that a large population of patients could benefit from semaglutide specifically to reduce adverse cardiovascular outcomes, regardless of their primary goal for weight management.
Re-evaluating Treatment Goals: The evidence supports prescribing semaglutide to protect the heart, even if a patient is not achieving the maximum possible weight reduction.

In summary, the SELECT trial analysis reinforces semaglutide’s role as a vital cardiovascular protective drug, suggesting its benefit is rooted in its pleiotropic effects on vascular health and inflammation, not just its impact on the scale.